Literature DB >> 34916694

[Susceptibility vessel sign in subacute stroke patients with large vessel occlusion].

G Y Ren1,2, X M Wu2, Y Li1, J Y Li1, W P Sun1, Y N Huang1.   

Abstract

OBJECTIVE: To investigate the presentation of susceptibility vessel sign (SVS) in subacute stroke patients with large vessel occlusion.
METHODS: We collected consecutive stroke patients who were admitted to Peking University First Hospital from December 2017 to August 2019 retrospectively. Those who had intracranial large vessel occlusion and received sensitivity weighted imaging (SWI) within 3 to 14 days after stroke onset were included in our analysis. The diagnosis of large vessel occlusion was based on magnetic resonance angiography (MRA), CT angiography (CTA) or digital subtraction angiography (DSA). The demographic information, clinical characteristics and imaging results were obtained from medical record. The occurrence rates of SVS sign were compared between stroke patients with cardioembolism (CE) and large artery atherosclerosis (LAA). In the sensitivity analysis, we performed a subgroup analysis in those patients who received SWI within 7 to 14 days after stroke onset. We also compared the occurrence rate of SVS sign between the patients with and without atrial fibrillation.
RESULTS: A total of 51 patients, 19 females and 32 males, with an average age of (63.04±11.23) years were analyzed in this study. Compared with LAA group, the patients in CE group were older and more likely to have an atrial fibrillation (P < 0.05). There were no significant differences between the CE group and LAA group in gender, hypertension, diabetes, coronary heart disease, hyperlipidemia, smoking, or National Institute of Health stroke scale(NIHSS) score at admission. SVS sign was found in 30 patients. Of whom, 3 were in CE group and 27 in LAA group. The occurrence rate of SVS sign was higher in the LAA group than in the CE group significantly (65.9% vs. 30.0%, P=0.039). The subgroup analysis showed that, in the patients who received SWI examination within 7 to 14 days after stroke onset, the differences between the two groups were still statistically significant (0 vs. 72.7%, P=0.006). Another sensitivity analysis showed that, the rate of SVS in the patients with atrial fibrillation was significantly lower than those patients without atrial fibrillation (25% vs. 65.1%, P=0.043).
CONCLUSION: In subacute stroke patients, the occurrence rate of SVS sign in CE group was lower than that of LAA group. The significance of SVS sign in the differentiation of stroke subtype needs further validation.

Entities:  

Keywords:  Etiological type; Large vessel occlusion; Stroke; Subacute stage; Susceptibility-weighted imaging

Mesh:

Year:  2021        PMID: 34916694      PMCID: PMC8695164     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  15 in total

1.  Thrombus components in cardioembolic and atherothrombotic strokes.

Authors:  Yuichiro Sato; Hatsue Ishibashi-Ueda; Takashi Iwakiri; Yoshihiko Ikeda; Takaaki Matsuyama; Kinta Hatakeyama; Yujiro Asada
Journal:  Thromb Res       Date:  2012-04-28       Impact factor: 3.944

2.  Platelet-Rich Emboli in Cerebral Large Vessel Occlusion Are Associated With a Large Artery Atherosclerosis Source.

Authors:  Seán Fitzgerald; Daying Dai; Shunli Wang; Andrew Douglas; Ramanathan Kadirvel; Kennith F Layton; Ike C Thacker; Matthew J Gounis; Ju-Yu Chueh; Ajit S Puri; Mohammed Almekhlafi; Andrew M Demchuk; Ricardo A Hanel; Eric Sauvageau; Amin Aghaebrahim; Albert J Yoo; Peter Kvamme; Vitor M Pereira; Yasha Kayan; Josser E Delgado Almandoz; Raul G Nogueira; Alejandro A Rabinstein; David F Kallmes; Karen M Doyle; Waleed Brinjikji
Journal:  Stroke       Date:  2019-05-29       Impact factor: 7.914

3.  Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke.

Authors:  E Mori; Y Yoneda; M Tabuchi; T Yoshida; S Ohkawa; Y Ohsumi; K Kitano; A Tsutsumi; A Yamadori
Journal:  Neurology       Date:  1992-05       Impact factor: 9.910

4.  Distribution and Temporal Trends From 1993 to 2015 of Ischemic Stroke Subtypes: A Systematic Review and Meta-Analysis.

Authors:  Raffaele Ornello; Diana Degan; Cindy Tiseo; Caterina Di Carmine; Laura Perciballi; Francesca Pistoia; Antonio Carolei; Simona Sacco
Journal:  Stroke       Date:  2018-03-13       Impact factor: 7.914

5.  Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke.

Authors:  C A Molina; J Montaner; S Abilleira; B Ibarra; F Romero; J F Arenillas; J Alvarez-Sabín
Journal:  Stroke       Date:  2001-05       Impact factor: 7.914

6.  Significance of susceptibility vessel sign on T2*-weighted gradient echo imaging for identification of stroke subtypes.

Authors:  Kyung-Hee Cho; Jong S Kim; Sun U Kwon; A-Hyun Cho; Dong-Wha Kang
Journal:  Stroke       Date:  2005-10-13       Impact factor: 7.914

Review 7.  Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier.

Authors:  Philip B Gorelick; Ka Sing Wong; Hee-Joon Bae; Dilip K Pandey
Journal:  Stroke       Date:  2008-06-05       Impact factor: 7.914

8.  The Underlying Stroke Etiology: A Comparison of Two Classifications in a Rural Setup.

Authors:  Avani R Patel; Amar R Patel; Soaham Desai
Journal:  Cureus       Date:  2019-07-17

9.  Comparison of susceptibility weighted imaging and TOF-angiography for the detection of Thrombi in acute stroke.

Authors:  Alexander Radbruch; Johanna Mucke; Ferdinand Schweser; Andreas Deistung; Peter Alexander Ringleb; Christian Herbert Ziener; Matthias Roethke; Heinz-Peter Schlemmer; Sabine Heiland; Jürgen R Reichenbach; Martin Bendszus; Stefan Rohde
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

10.  Prediction of Stroke Subtype and Recanalization Using Susceptibility Vessel Sign on Susceptibility-Weighted Magnetic Resonance Imaging.

Authors:  Dong-Wan Kang; Han-Gil Jeong; Do Yeon Kim; Wookjin Yang; Seung-Hoon Lee
Journal:  Stroke       Date:  2017-04-21       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.